Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • pettervikman
    Member
    • Nov 2009
    • 23

    Cufflinks -g option yields many 0 FPKM transcripts and annotates them interestingly

    Hi

    I've just started using the -g option in the newest version of cufflinks. I've found that it then creates a whole bunch of transcripts that are specified as 0 in the FPKM, as well as in high low conf. FPKM columns. It's easy to filter this after but I find that it's interesting that they are created initially.

    Second I've found that when looking in the GENES file the transcripts are tagged as OK or LOWCOVERAGE. Here transcripts with a low-conf FPKM of 0 and any of the other FPKM fields above 0 are flagged as lowcoverage while transcripts with FPKM of 0 and all fields > 0 are OK. Once again it's easy to change the OK to not expressed or similar but it would be nice to not having to do this.

    So my questions are 1, has anybody else seen this and 2, have anyone information regarding how "true" the prescence of transcripts are?

    Sincerely

    /Petter
  • jhb1980
    Junior Member
    • Dec 2010
    • 7

    #2
    Hi Petter,

    I'm still pretty new to this all, so if anyone spots a wrong statement below, please feel free to point it out.

    As for question 1, I think this is an inherent property of the -g (RABT) option, which tiles reference transcripts with faux reads wether the transcript is expressed in your sample or not (see http://cufflinks.cbcb.umd.edu/howitworks#hrga ). If you take your output through Cuffcompare, the "-R" option should remove any reference *.gtf transcript not expressed.

    As for question 2, I don't think this is a trivial one and pretty much an own topic of research. The best ways (from a biological point of view) in my opinion would be to see if a) the transcript expression / (structure) is reproducible between replicates; and b) if the transcript is still detected when using higher mapping stringency (mismatch allowance, multimapper limit), i.e. "playing around" with the input parameters of the Mapper and Assembler. The first point of course raises your invoice considerable .

    Comment

    • pettervikman
      Member
      • Nov 2009
      • 23

      #3
      Hi

      Thanks for the reply. I've realised that the output annotation is a bit unprecise, or I don't understand the labelling. Transcripts with 0 coverage and 0 in all positions except the highFPKM are labelled OK for example.

      Anyhow, I have 48 samples and I've decided to filterout anything that is not present in at least two samples. After that I'll see what I have left.

      /Petter

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
        by SEQadmin2


        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

        The systematic characterization of the human proteome has
        ...
        Yesterday, 11:48 AM
      • SEQadmin2
        Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
        by SEQadmin2



        Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
        ...
        07-09-2026, 11:10 AM
      • SEQadmin2
        Cancer Drug Resistance: The Lingering Barrier to Rising Survival
        by SEQadmin2



        Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

        There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
        07-08-2026, 05:17 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, Yesterday, 11:10 AM
      0 responses
      8 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-13-2026, 10:26 AM
      0 responses
      30 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-09-2026, 10:04 AM
      0 responses
      39 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-08-2026, 10:08 AM
      0 responses
      25 views
      0 reactions
      Last Post SEQadmin2  
      Working...